{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:21:39Z","timestamp":1790490099497,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI117740"],"award-info":[{"award-number":["R01AI117740"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jconrel.2018.12.027","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T07:58:20Z","timestamp":1545119900000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-4305","authenticated-orcid":false,"given":"Subhra","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Kumar","family":"Prathipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Destache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.12.027_bb0005","series-title":"UNAIDS Factsheet","author":"UNAIDS Global Statistics \u2013 2015","year":"2016"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"Baeten","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0020","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0030","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Study, Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0045","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0050","doi-asserted-by":"crossref","first-page":"e28238","DOI":"10.1371\/journal.pone.0028238","article-title":"Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study","volume":"7","author":"Eisingerich","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0065","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Oral TAF\/FTC PrEP prevents vaginal SHIV infection in monkeys","author":"Mascolini","year":"2018"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0070","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF","author":"Garrett","year":"2016"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0075","series-title":"AIDS Map","article-title":"Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low","author":"Lerma","year":"2016"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0080","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","article-title":"Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission","volume":"31","author":"Mandal","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0090","first-page":"61","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0095","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jpba.2016.07.040","article-title":"Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS\/MS and its application to a pharmacokinetic study","volume":"129","author":"Prathipati","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0100","unstructured":"Bioanalytical Method Validation in Guidance for Industry., in: F.a.D.A. Department of Health and Human Services (Ed.), CVM, CDER, 2013, pp. 2\u20139."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0105","series-title":"Construction of human-SCID chimeric mice, current protocols in immunology, chapter 4","author":"Roncarolo","year":"2001"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0110","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1073\/pnas.1318175111","article-title":"Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0115","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0120","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nature03513","article-title":"Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells","volume":"434","author":"Li","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0125","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1128\/JVI.71.9.7080-7082.1997","article-title":"The relationship between tumor necrosis factor and human immunodeficiency virus gene expression in lymphoid tissue","volume":"71","author":"Li","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0135","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0b013e3283543e83","article-title":"Antiviral agents and HIV prevention: controversies, conflicts, and consensus","volume":"26","author":"Cohen","year":"2012","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0140","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/clpt.2010.189","article-title":"Pharmacologic opportunities for HIV prevention","volume":"88","author":"Nicol","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0145","doi-asserted-by":"crossref","first-page":"270ra274","DOI":"10.1126\/scitranslmed.3010298","article-title":"A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0150","doi-asserted-by":"crossref","first-page":"270ra275","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAI.0000000000000607","article-title":"Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: importance of adherence for microbicide effectiveness","volume":"69","author":"Kashuba","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0160","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments","volume":"8","author":"Hendrix","year":"2013","journal-title":"PLoS One"},{"issue":"2014","key":"10.1016\/j.jconrel.2018.12.027_bb0165","first-page":"340","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0170","doi-asserted-by":"crossref","first-page":"e5146","DOI":"10.1097\/MD.0000000000005146","article-title":"The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0175","doi-asserted-by":"crossref","first-page":"112re114","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.virol.2014.07.008","article-title":"HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model","volume":"464\u2013465","author":"Veselinovic","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2018.12.027_bb0185","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jac\/dkx064","article-title":"Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues","volume":"72","author":"Cottrell","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2018.12.027_bb0190","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/jac\/dku162","article-title":"Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission","volume":"69","author":"Anderson","year":"2014","journal-title":"J. Antimicrob. Chemother."}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2019.05.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T12:06:58Z","timestamp":1610539618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918307302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"alternative-id":["S0168365918307302"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.027","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jconrel.2019.05.002","asserted-by":"object"}]},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}